BOOM
Recent additions may not be included but will usually appear in 24 hrs or less.
| Rational | Source |
|---|---|
|
Beneficial effects of GABA-producing potential probiotic Limosilactobacillus fermentum L18 of human origin on intestinal permeability and human gut microbiota. ✅
Go to Publication ✅
Microbial cell factories (Microb Cell Fact ) Vol: 22 Issue 1 Pages: 256 Pub: 2023 Dec 12 Epub: 2023 Dec 12 Authors Kaur S , Sharma P , Mayer MJ , Neuert S , Narbad A , Kaur S , |
|
|
Limosilactobacillus fermentum CECT5716: Clinical Potential of a Probiotic Strain Isolated from Human Milk. ✅
Go to Publication ✅
Nutrients (Nutrients ) Vol: 15 Issue 9 Pages: Pub: 2023 May 6 Epub: 2023 May 6 Authors Ozen M , Piloquet H , Schaubeck M , |
|
|
Probiotic effects of Lacticaseibacillus rhamnosus 1155 and Limosilactobacillus fermentum 2644 on hyperuricemic rats. ✅
Go to Publication ✅
Frontiers in nutrition (Front Nutr ) Vol: 9 Issue Pages: 993951 Pub: 2022 Epub: 2022 Sep 30 Authors Li Y , Zhu J , Lin G , Gao K , Yu Y , Chen S , Chen L , Chen Z , Li L , |
|
|
Probiotic effects of Lacticaseibacillus rhamnosus 1155 and Limosilactobacillus fermentum 2644 on hyperuricemic rats. ✅
Go to Publication ✅
Frontiers in nutrition (Front Nutr ) Vol: 9 Issue Pages: 993951 Pub: 2022 Epub: 2022 Sep 30 Authors Li Y , Zhu J , Lin G , Gao K , Yu Y , Chen S , Chen L , Chen Z , Li L , |
|
|
A Mix of Potentially Probiotic Limosilactobacillus fermentum Strains Alters the Gut Microbiota in a Dose- and Sex-Dependent Manner in Wistar Rats. ✅
Go to Publication ✅
Microorganisms (Microorganisms ) Vol: 12 Issue 4 Pages: Pub: 2024 Mar 26 Epub: 2024 Mar 26 Authors Carneiro Dos Santos LA , Carvalho RDO , Cruz Neto JPR , de Albuquerque Lemos DE , de Oliveira KÁR , Sampaio KB , de Luna Freire MO , Aburjaile FF , Azevedo VAC , de Souza EL , de Brito Alves JL , |
|
|
Revealing the Potential Impacts of Nutraceuticals Formulated with Freeze-Dried Jabuticaba Peel and Limosilactobacillus fermentum Strains Candidates for Probiotic Use on Human Intestinal Microbiota. ✅
Go to Publication ✅
Probiotics and antimicrobial proteins (Probiotics Antimicrob Proteins ) Vol: 16 Issue 5 Pages: 1773-1789 Pub: 2024 Oct Epub: 2023 Aug 10 Authors da Silva JYP , do Nascimento HMA , de Albuquerque TMR , Sampaio KB , Dos Santos Lima M , Monteiro M , Leite IB , da Silva EF , do Nascimento YM , da Silva MS , Tavares JF , de Brito Alves JL , de Oliveira MEG , de Souza EL , |
|
|
Lactobacillus fermentum Inhibits the Development of Colitis by Regulating the Intestinal Microbiota and Metabolites to Enhance the Intestinal Barrier and Decrease Inflammatory Responses. ✅
Go to Publication ✅
International journal of molecular sciences (Int J Mol Sci ) Vol: 26 Issue 18 Pages: Pub: 2025 Sep 19 Epub: 2025 Sep 19 Authors You X , Shi P , Liu W , Zheng M , Jin L , Liu W , |
|
|
Limosilactobacillus fermentum 2L Ameliorates Chronic Stress-Induced Neuroinflammation through Gut-Brain Axis Modulation in Mice. ✅
Go to Publication ✅
Journal of microbiology and biotechnology (J Microbiol Biotechnol ) Vol: 35 Issue Pages: e2509035 Pub: 2025 Nov 26 Epub: 2025 Nov 26 Authors Joung JY , Cheon S , Song JG , Han C , So JS , Moon JK , Kim HW , Kim SH , |
BOOM
All suggestions are computed solely on their predicted microbiome impact. Safety, side-effects etc must be evaluated by your medical professionals before starting. Some items suggests have significant risk of adverse consequences for some people.
Special thanks to David F Morrison and Geert Van Houcke for doing Quality Assurance. Special thanks to Oliver Luk, B.Sc. (Biology) from BiomeSight for spot checking the coding of data from the US National Library of Medicine
This is an Academic site. It generates theoretical models of what may benefit a specific microbiome results.
Copyright 2016-2023 Lassesen Consulting, LLC [2007], DBA, Microbiome Prescription. All rights served.
Permission to data scrap or reverse engineer is explicitly denied to all users. U.S. Code Title 18 PART I CHAPTER 47 § 1030, CETS No.185, CFAA
Use of data on this site is prohibited except under written license. There is no charge for individual personal use. Use for any commercial applications or research requires a written license.
Caveat emptor: Analysis and suggestions are based on modelling (and thus infererence) based on studies. The data sources are usually given for those that wish to consider alternative inferences. theories and models.
Inventions/Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions, or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not Health Insurance Portability and Accountability Act of 1996 (HIPAA) compliant.
